viewSilence Therapeutics PLC

Silence Therapeutics feels move to NASDAQ will give its tech the 'recognition it deserves'

Silence Therapeutics PLC's (LON:SLN) chairman Iain Ross and CFO Rob Quinn speak to Proactive London's Andrew Scott after announcing its intention to list on the American growth market, Nasdaq.

Ross says in the US, RNAi is very hot at the moment and if you look at their competitor companies they're valued at a 'great deal more' than Silence.

''While we might not quite be at the same stage as they are in terms of development and number of deals we feel the company will be revalued in time''.

Quick facts: Silence Therapeutics PLC

Price: 464.187 GBX

Market: AIM
Market Cap: £384.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...



Morning Report: FTSE 100 falls as Rolls-Royce confirms 9000 job cuts

Headlines from Proactive UK newsroom. The FTSE100 made a nervy start on doubts that Moderna’s Covid-19 vaccine will pass muster. The blue-chip index dipped 30 points to 5,971. Rolls-Royce has confirmed it will shed 9,000 jobs from its global workforce of 52,000. The cuts are part of a...

1 week, 6 days ago

2 min read